Craft

ProPhase Labs

Stock Price

$2.3

2024-10-29

Market Capitalization

$42.9 M

2024-10-29

Revenue

$6.8 M

FY, 2024

ProPhase Labs Summary

Company Summary

Overview
ProPhase Labs develops and markets clinically proven remedies including the highly effective Cold-EEZE and Kids-EEZE product lines. The Company's ongoing objective is to deliver long-term value by providing exceptional new products that address the health care and quality of life concerns of the broadest market segments.
Type
Public
Status
Active
Founded
1981
HQ
Doylestown, PA, US | view all locations
Website
http://prophaselabs.com
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Ted Karkus, Chairman & CEO

    • Jason Barr, Director

      • Louis Gleckel, Director

        • Warren Hirsch, Director

          LocationsView all

          3 locations detected

          • Doylestown, PA HQ

            United States

          • Old Bridge, NJ

            United States

            42 Throckmorton Ln

          • Uniondale, NY

            United States

            711 Stewart Ave Suite 200, Hempstead

          ProPhase Labs Financials

          Summary Financials

          Revenue (Q3, 2025)
          $883.0K
          Gross profit (Q3, 2025)
          ($123.0K)
          Net income (Q3, 2025)
          ($6.8M)
          Cash (FY, 2025)
          $90.0K
          EBIT (Q3, 2025)
          ($4.8M)
          Enterprise value
          $44.0M

          Footer menu